Antivirals
| |
|
|
| |
| Table 7-2 Oral Antiviral Drugs |
| |
Name |
|
Mechanism of Action |
|
Spectrum, Pregnancy Category |
|
Miscellaneous |
| |
Acyclovir |
|
Phosphorylated by viral
thymidine kinase to
acyclovir monophosphate,
which blocks viral DNA
polymerase → stops viral
DNA synthesis |
|
Herpes simplex virus (HSV), varicella-
zoster virus (VZV)
Pregnancy category B |
|
SE: IV infusion associated with
reversible obstructive nephropathy,
rarely may see severe CNS
Pregnancy category B changes (i.e., seizures) |
| |
Valacyclovir |
|
Prodrug of acyclovir, same
mechanism of action (viral
thymidine kinase-dependent
activity) |
|
HSV, VZV,
cytomegalovirus (CMV)
Category B |
|
Better bioavailability than
acyclovir
SE: TTP/HUS* seen in advanced
HIV disease and transplant
patients taking high doses |
| |
Penciclovir |
|
Phosphorylated by viral
thymidine kinase (similar
mechanism to acyclovir) |
|
HSV, VZV |
|
Low bioavailability so typically
used in topical form |
| |
Famciclovir |
|
Prodrug of penciclovir with
same mechanism as above |
|
HSV, VZV
Category B |
|
Better bioavailability than
Category B penciclovir |
| |
Ganciclovir |
|
Phosphorylated by viral
thymidine kinase; same
mechanism as above |
|
CMV (retinitis)
Category C |
|
Better activity against CMV than
acyclovir; ↓ oral bioavailability
SE: neutropenia, bone marrow
suppression, mucositis,
thrombocytopenia, seizures
hepatic dysfunction |
| |
Foscarnet |
|
Noncompetitive inhibition
of viral DNA polymerases;
analogue of pyrophosphate
Does not require phosphorylation so active against
acyclovir-resistant viruses |
|
CMV (retinitis), resistant HSV,
resistant VZV
Category C |
|
Only IV form; active against
infections resistant to acyclovir,
famciclovir, ganciclovir
SE: penile ulcerations
or erosions, nephrotoxicity |
| |
Cidofovir |
|
Nucleoside analogue,
inhibits viral DNA polymerase, independent of
thymidine kinase
activation |
|
CMV
Category C |
|
IV only; active against infections
resistant to ganciclovir/foscarnet
SE: renal proteinuria, renal
toxicity, ↑ creatinine |
| |
Amantidine,
Rimantidine |
|
Inhibit uncoating of viral
DNA within infected host
cells (prevents replication) |
|
Influenza A/C, rubella
Category C |
|
SE: anticholinergic symptoms,
Category C ataxia, and photosensitivity |
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
*TTP: thrombotic thrombocytopenic purpura
HUS: hemolytic uremic syndrome |
|
|
| |
|
|
|
| |
|
|
| |
| Table 7-3 Antiretroviral Drugs |
| |
Name |
|
Mechanism of Action |
|
Characteristics |
| Nucleoside/nucleotide reverse transcriptase inhibitors |
| |
Zidovudine (AZT) |
|
Thymidine analogue, inhibits HIV
reverse transcriptase (RT) |
|
SE: melanonychia, mucocutaneous
pigmentation, bone marrow suppression,
lipodystrophy
Pregnancy category C |
| |
Didanosine (ddI) |
|
Pyrimidine analogue, similar to AZT |
|
SE: pancreatitis, optic neuritis, peripheral
neuropathy, lactic acidosis; pregnancy category B |
| |
Abacavir (ABC) |
|
Nucleoside RT inhibitor |
|
SE: hypersensitivity reaction
(can be fatal upon rechallenge)
Pregnancy category C |
| |
Tenofovir |
|
Nucleotide analogue, inhibits RT |
|
Peripheral wasting, cushingoid appearance
Pregnancy category B |
| Protease inhibitors |
| |
Indinavir, Ritonavir,
Lopinavir |
|
Block HIV-1 protease enzymes |
|
SE: lipodystrophy (buffalo hump), gynecomastia, periungual pyogenic granulomas, paronychia,
hepatotoxicity |
| |
|
|
|
|
|
|
|
| |
|
|
|
|